Jeffrey Friedman
Radiation Oncology · Gallatin, TNNPI 1235427220
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $403 and has fallen 51.7% since, to $195 in 2025.
Across 49 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$194
- Amgen$148
- Palette Life Sciences, Inc.$136
- Bayer$75
- Boston Scientific$69
- Varian Medical Systems, Inc.$57
- plus $434 from 17 others
What the payments were for
- Food & beverage$1,113100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $194 |
| Amgen | 9 | $148 |
| Palette Life Sciences, Inc. | 1 | $136 |
| Bayer | 4 | $75 |
| Boston Scientific | 3 | $69 |
| Varian Medical Systems, Inc. | 2 | $57 |
| Bioprotect Medical, Inc. | 2 | $49 |
| Bristol Myers Squibb | 2 | $49 |
| Eisai Inc. | 2 | $45 |
| Myriad Genetic Laboratories, Inc. | 1 | $30 |
| Blue Earth Diagnostics | 1 | $28 |
| Novartis | 2 | $26 |
| Foundation Medicine, Inc. | 2 | $26 |
| Coherus Oncology, Inc. | 1 | $26 |
| Teleflex LLC | 1 | $24 |
| Sanofi | 1 | $21 |
| Merck | 1 | $18 |
| Progenics Pharmaceuticals, Inc. | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
How this compares
$1,113 in reported general payments places this provider in the 65th percentile of 115 radiation oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 62 | $777 |
| Sucralfate | 18 | $680 |
| Gabapentin | 14 | $260 |
| Mupirocin | 28 | $251 |
| Dexamethasone | 20 | $186 |
| Fluconazole | 12 | $110 |
| SsdSilver Sulfadiazine | 12 | $108 |
| Tamsulosin Hcl | 13 | $71 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Gallatin
- Han-Chih ChangNashville$66K
- Karen WinkfieldNashville$53K
- James GrayNashville$46K
- David RobergeMemphis$28K
- Matthew BalloMemphis$25K
- John PhillipsNashville$23K
- Casey LipscombNashville$23K
- Andrew KennedyNashville$18K
- Anthony CmelakNashville$16K
- Daniel WakefieldMemphis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.